The continued implementation of NMR-based approaches in hit-through-lead drug discovery in academic and corporate settings is founded upon NMR applications that assess structure activity relationships. A very recent application of NMR spectroscopy to these discovery initiatives involves fraganomics, in which NMR is used to iteratively "guide" the assembly of several weakly interacting fragments or small molecules through chemical links. Moreover, several groups have recently reported the potential of integrating NMR spectroscopy with in silico, virtual screens of large chemical repositories possessing diverse collections of small molecules. Importantly an improved understanding of the intermolecular forces that mediate protein-protein/ protein-ligand interactions has been integral to improving these virtual screening approaches, resulting in the identification of novel ligands for several therapeutic targets. Recent success of these structure-based discovery initiatives in targeting protein-protein interactions that are responsible for the non-covalent assembly and/or regulation of macromolecular complexes and are a critical paradigm in many disease pathologies will be discussed. The atomic details of these requisite interactions are the cornerstone of NMR and crystallographic "structure-guided", drug discovery initiatives aimed at disrupting complex formation. This review will predominantly focus on the recent advances in structure based computational screening approaches, highlighting the successful integration of in silico virtual screens with NMR-based techniques. The application of this powerful, combinatorial approach for the evaluation of well-characterized target space as well as its application to unique chemical space such as the protein-protein interaction inhibition (2P2I) that has recently been shown to be tractable to small molecule intervention will be discussed.
INTRODUCTION
The Human Genome Project [1] has identified approximately 30,000 genes in the human genome, with a subset of these genes, ~3,000-10,000, believed to be involved in the pathogenesis of disease [2, 3] . In a comprehensive review of pharmaceutical industry portfolios Drews and colleagues identified approximately 500 drug targets, but suggested there are likely as many as 5,000-10,000 potential therapeutic targets [4, 5] . However, they caution that many of these potential targets remain underexploited since they are believed to be intractable to orally bioavailable small molecules [4, 6, 7] . That said, most commercial drug discovery initiatives continue to develop and/or expand their pre-clinical and clinical pipelines, focusing on G-protein coupled receptors (GPCR's), nuclear receptors, ion channels and enzymatic targets [3, 5] . While most drugs on the market are competitive inhibitors of these targets, there remains a significant unmet clinical need in many disease indications, a predicament that is likely to worsen due to the emergence of serious clinical complications with current therapeutic drugs [8, 9] . Corporate *Address correspondence to these authors at the CNRS-IBSM/BIP Laboratory, 31 Chemin Joseph Aiguier, 13402 Marseille, Cedex 20, France; E-mail: morelli@ibsm.cnrs-mrs.fr or Division of Molecular and Vascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02215, USA; E-mail: arigby@bidmc.harvard.edu "hit through lead" portfolios are often biased to placate market forces, in an attempt to deliver "best-in-class" drugs [4, 5, 7, 10] . The late stage "false positive" triage of compounds enrolled in research-intensive optimization is expensive. Structure-based and/or ligand-based virtual screening efforts that are partnered with structural biology methods including X-ray crystallography and/or nuclear magnetic resonance (NMR) spectroscopy provide a cost effective, streamlined approach for identifying hits and validating leads prior to further preclinical and clinical evaluation [11] [12] [13] . Alone these approaches have their own merit in discovery pipelines, however it is the combination of these approaches, specifically NMR with structure-based in silico screening that will be the focus of this review.
In an attempt to expand what is considered to be a therapeutically drugable target, several groups have capitalized on the structural genomic initiatives that continue to provide new structures and the interaction proteome that defines how these protein-protein interactions are assembled [14] [15] [16] [17] [18] . Protein-protein molecular recognition is the cornerstone of cellular function and mechanistic signal transduction. Success in targeting these protein-protein interfaces, which are classically comprised of relatively flat, featureless surfaces devoid of cavities and/or pockets that are critical for ligand specificity and affinity, has been difficult [19] . Nonetheless, these protein-protein interfaces represent therapeutically interesting and commercially lucrative target space ( [20] and references therein). The long-standing notion In an attempt to meet current unmet clinical needs, drug discovery programs are currently using data provided by structural proteomic initiatives and the interaction proteome to search of novel therapeutic targets involved in these disease indications. If the 3D structure of the target is known the drug discovery strategy proceeds to hit identification, which is the identification of small molecules that possess in vitro/in vivo function and are comprised of lead-like PK and PD properties. However, as is often the situation when exploring new 3D target space, NMR spectroscopy, X-ray crystallography or homology model-based approaches are first needed for structure determination. Using this target structure one should initially evaluate its drugability using any one of a number of approaches including the NMR approach recently proposed by Hajduk and colleagues at Abbott Laboratories [21] . If the target is deemed drugable according to the metrics evaluated, the search for "small molecule hits" is commenced. NMR is an important tool for "hit" identification that involves a medium throughput NMR-based binding assay, chemical shift perturbation analysis (CSP), SAR by NMR, SAR by ILOE or other fragment-based approaches. Hits identified can be further evaluated for specificity and/or non-specific target reactivity using NMR approaches such a RAMPED-UP NMR and/or ALARM NMR [63, 78, 163] . Validated hits are then optimized using hit-through-lead approaches, which often involve medicinal chemistry and Quantitative Structure Activity Relationships (QSAR) that are iteratively evaluated by NMR [71] . The ultimate goal is a bioavailable small molecule with optimized PD/PK properties for subsequent pre-clinical and ultimately clinical evaluation. that these interfaces are excessively complicated and thus "poorly drugable" is founded on the inherent threedimensional (3D), biophysical complexity of this target space [19, 20] . Although these protein-protein interfaces were believed to be refractory to small molecule intervention, an improved understanding of these complex surfaces and the relative energetic contributions bestowed by; interface shape, interface size, geometrical complexity, polarity and roughness have recently stimulated renewed interest in this target space [19, 21] . The typical protein-protein interface is 750-1500 Å 2 , however the notion of "interaction hot spots", which contribute a disproportionate amount of binding energy to the interaction, has provided a unique target strategy for the identification of small molecule "hits", which are compounds that are likely to posses in vitro and/or in silico activity [20] . These hot spots tend to reside on both proteins and are clustered within the interaction interface, thereby contributing in a co-operative manner to the formation of the complex through surface complementary and significant protein flexibility [22] . However, the combination of target complexity and limited chemical space sampling within the "drug-like" chemical repositories that are typically screened in small molecule High Throughput Screens (HTS) has created both a experimental and intellectual barrier, limiting the therapeutic utility of these targets [20] . As recently as 2001 the widely held belief in drug discovery initiatives was that these interactions would likely remain intractable to 'Lipinsky rule of 5'-compliant, small molecule therapies [23] [24] [25] .
One promising approach for the discovery of small molecule "hits" for this under-exploited target space is fragment-based lead discovery or fraganomics, whereby small, relatively simple fragments are evaluated for their ability to bind to a target and provide a scaffold or substrate for further medicinal chemistry and/or chemical ligation to another targeted fragment [26, 27] . Successful fragment screening requires a biophysical screening approach that is capable of detecting relatively weak interactions while providing an observable window through which the linkage and subsequent interaction of these proximal fragments with the target can be monitored ( [28] [29] [30] and references therein). Nuclear magnetic resonance spectroscopy (NMR) provides a robust platform to characterize both the ligand binding site and affinity, while simultaneously providing a window through which the entire target protein or proteins can be structurally observed without the need of an assay for detecting this interaction. The ability of NMR to provide detailed structural information pertaining to target proteins and the newly identified hits or leads being optimized has facilitated the integration of NMR into many translational discovery programs in both corporate and academic settings (Fig. (1) ). Fraganomics and other approaches that combine virtual screening and structural biology approaches such as NMR continue to contribute to the growing knowledgebase of improved scaffold diversity within small molecule "hits" and "leads" that are capable of inhibiting protein-protein interactions, including the nutlins, which inhibit the interaction between p53 and human double minute-2 ( H D M 2 ) as well as compounds that inhibit the heterodimerization of BCL2 family members including those involving BCL2 and BCL-X L [31] [32] [33] [34] . While several examples of these successes will be highlighted a detailed discussion of this work is beyond the scope of this review.
As we improve our understanding of the varied interactions that mediate molecular recognition at the cellular and/or structural level, one goal is to better understand and thus overcome the challenges associated with identifying novel, small molecule therapies. This will only happen if the movement afoot to strengthen the iterative integration of biophysical and computational approaches continues, ensuring new strategies are developed, evaluated, refined and ultimately integrated into discovery programs. Here we review NMR spectroscopic and High Throughput Docking (HTD) approaches that are being implemented in commercial and academic drug discovery initiatives to circumvent "bottlenecks" encountered in traditional hit-through-lead drug discovery. Additionally, we will emphasize the utility and power of coupling NMR with structure-based HTD to accelerate discovery processes. Limitations in the scoring algorithms used to reproducibly rank identified "hits" within structure-based drug discovery initiatives have slowed the adoption of structure and/or ligand-based approaches although many laboratories are focused on improving the accuracy and reproducibility of these scoring functions ( [35] [36] [37] [38] and references therein). We will present several docking strategies and comment on current scoring algorithm limitations, documenting improvements in both of these areas that have resulted in demonstrable successes and argues for the adoption of this combinatorial approach [39] . While structure-based virtual screening or NMR approaches for hit identification alone suffer from inherent caveats and/or limitations, it is the powerful combination of these approaches that will be the focus of this review. Others have extensively commented on and demonstrated the strength and utility of partnering homology-based structure determination with these in silico approaches. While this is an important area of discovery research that has generated several hits and/or drugs we will not discuss it further, however several excellent papers documenting this approach and its success are provided (and references therein [11, [40] [41] [42] ). Here we highlight several recent successes that use this combined strategy to target protein-protein and proteinligand interfaces, and other novel target space which had previously been perceived as too complex for small molecule, 'rule of 5-compliant' intervention, yet now represents an exciting paradigm shift in therapeutic intervention [43, 44] .
STRUCTURE BASED COMPUTATIONAL DRUG DISCOVERY
Computer aided drug discovery (CADD) approaches for screening virtual libraries in silico that are theoretically comprised of 10 100 molecules is a promising tool for exploring new and expanded chemical space. CADD approaches are likely to accelerate hit identification, and subsequent lead validation and optimization, to provide leads that are potentially more therapeutically viable [39, 45] . In silico computational mining of three-dimensional databases or libraries using either a pharmacophore that is comprised of critical functional determinants or target-based HTD, which facilitates the rapid screening of the molecular surface or target "active site" with members of a virtual compound library offers several advantages over experimental HTS, but is not without its own limitations and caveats (Fig. (2) ). However, an extensive study carried out by the Shoichet laboratory nicely demonstrated that for several targets experimental HTS and/or in silico screening provided complimentary data of use to these discovery communities [46] . As we will discuss structure-based virtual screening uses critical structural descriptors that are extracted from the target protein (alone or in complex with endogenous ligand) and defined using biophysical approaches including but not limited to NMR spectroscopy. These pharmacophores guide and structurally filter HTD approaches that evaluate large chemical repositories for "hits" that satiate these requirements using an approach that is both efficient and cost effective.
Many of the important advances in the use of NMR in drug discovery have been and continue to be reliant on recombinant expression of target proteins in E. coli bacterial expression systems that facilitate the preparation of adequate quantities of isotopically enriched target protein. In addition, these recombinant approaches allow us to readily optimize construct development for the expression of proteins and/or protein domains that are folded and amenable to solution studies in the concentration range needed for NMR spectroscopy. In an attempt to provide NMR data of the highest quality the solution conditions are often optimized using strategies such as micro-drop that permit one to easily evaluate; buffer salt, pH, the need and/or concentration of stabilizer as well as temperature at which the studies will be carried out [47] . Unfortunately, these and other inherent limitations of NMR and/or X-ray crystallography have precluded the use either approach for many targets including membrane proteins such as GPCR's, which represent a single family of receptors that are involved in many signal A) If there are no known inhibitors of the target being explored or the target represents unique target space, the first step (following the previously detailed structural study) in the 2P2I discovery flowchart involves HTD of a diverse 3D database representing many chemical scaffolds (1K to 50K compounds). The diversity of this initial library is critical for optimizing the chemical space being evaluated. We propose that our generalist/consensus scoring function (GFscore) should then be used to score and rank the "hits/ small molecules" that dock within the target space (500 to 2K compounds). Having enriched the proprietary or publicly accessible database using these in silico approaches we suggest performing experimental HTS on a portion of this same library in an attempt to enrich for hits that have demonstrable biological function and are not toxic within this subset of compounds. A comparison of the in silico and experimental HTS experiments will be used to further refine/optimize the scoring function. This specific scoring function and the preliminary hits that are obtained from the proposed "in silico Screening Protocol" will be used to screen the entire database comprised of (1M to 10M compounds representing increased chemical space). B) Having optimized and refined the HTD protocol that incorporates the refined scoring function, which identified true positives that were subsequently validated using experimental HTS from a diverse subset of the library, we suggest that the entire database including these "hits" are screened in silico (1M to 10M compounds). These hits are then evaluated through in vitro and/or in vivo assays to determine if compounds within this identified hit list (500 to 2K compounds) are lead compounds. 2D and 3D QSAR modeling (with CoMFA) can also be used, where necessary as well as combinatorial chemistry approaches to ensure that the chemical space being explored has been optimized within the entirety of the database screened (10 to 100 compounds). Prior to clinical evaluation it is necessary that the lead compound is rigorously evaluated for ADME, PD and PK properties ensuring clinical efficacy without deleterious side effects. The originality of the proposed 2P2I approach (A and B) resides in the fact that an acceleration of the process is possible since A) enriches or selects for a subset of molecules to be further used in defining the chemical space and the scoring parameters needed to reproducibly identify small molecule protein-protein interaction inhibitors when no known inhibitors are available.
transduction pathways, and more importantly are believed to be requisite in many metabolic and signaling pathways ( [48] and references therein). Despite the absence of highresolution structural data for many membrane protein families the discovery of small molecule therapies continues to increase with ~2000 new patents filed each year for drugs and/or small molecules that target select membrane protein families [48] . Using static or magic angle spinning (MAS) solid state NMR approaches and novel expression vectors for this family of proteins, a wealth of recently developed dynamic and ligand binding data offers new promise in structure-based discovery initiatives of membrane proteins [48] [49] [50] [51] . While important, solid-state approaches in drug discovery will not be discussed further. For a comprehensive review of the current state of this field the reader is referred to an excellent review recently published by Dr. Anthony Watts [48] . This review will focus on the use of solution NMR spectroscopy, which since the advent of structure activity relationships (SAR) by NMR has been the principal NMR method for fragment-based lead screening of protein-ligand interactions, although other approaches have been developed, and integrated into the biochemical and biophysical arsenal of NMR screening platforms ( [29, 52, 53] and references therein).
INTEGRATION OF NMR INTO DRUG DISCOVERY
NMR is an established method for the three-dimensional structure determination of small proteins (≤ 40 kDa) and is an archetypical method for characterizing the molecular dynamics that are critical for macromolecular complex assembly ( [52, 54] and references therein). In recent years the molecular mass range amenable to structure determination by NMR has increased significantly (> 50 kDa) with the development of triple resonance pulse sequence technologies, increased magnetic field strengths and heteronuclear recombinant protein expression methodologies [52, [55] [56] [57] . Similarly, the use of residual dipolar couplings, selective and/or segmental labeling strategies and the use of transverse relaxation optimized spectroscopy (TROSY), provides an optimized biophysical tool amenable to the study of complex macromolecular systems [58] [59] [60] [61] [62] . Importantly, the ability of NMR spectroscopy to provide structural details for protein-protein and protein-ligand interaction interfaces in protein complexes well beyond 100 kDa is invaluable for translating these binding data into interaction interfaces that are now, as previously noted, viable targets in an emerging paradigm of discovery initiatives in search of novel small molecule therapeutics [29, 52] .
The increasing prevalence of NMR spectroscopy in drug discovery pipelines is centered around the ability of NMR to detect ligand binding over many affinity ranges, while also providing a detailed structural picture of the entire target and permitting the identification of the specific ligand binding site ( [63] and references therein) (Fig. (1) ). Furthermore, NMR-based HTS, fragment screening or "fraganomics", SAR by NMR, and other NMR applications involved in hit through lead validation and optimization have been integrated into many discovery pipelines to facilitate earlier stage "false positive" triage ( [57] and references therein). The success of these NMR-based approaches supports an increasingly important role for NMR in both ligand and target validation, which is likely to become increasingly significant as we extend the boundaries of conventional target space [64] .
HIT IDENTIFICATION

Chemical Shift Perturbation Analysis
In addition to providing detailed structural information pertaining to newly identified drugable targets, NMR spectroscopy is the preferred method for characterizing the structural perturbations resulting from protein-protein and/or protein-ligand interactions over several affinity ranges. Ligand-induced localized changes of the chemical environment of nuclei that are within the recognition/binding site results in chemical shift perturbations (CSP) of those resonances critical for binding [52, 65] . If the ligand binding exchange rate is fast on the NMR chemical shift timescale, which suggests that 1/τ is faster than the chemical shift difference between the bound and free states of the ligand (τ is the lifetime), an average chemical shift for each resonance is observed and easily followed as a function of ligand added. In the fast exchange regime (<10 -5 M) these chemical shift data provide an estimate of the dissociation constant, K d that is calculated by correlating binding site chemical shift perturbation as a function of total ligand concentration (assuming that K on for complex formation is diffusion limited) [52, 66] . Chemical shift perturbation analysis is an integral component of many drug discovery pipelines, due to the ease of data collection and analysis. Similarly, if the structure of the target is known these data are invaluable for translating these binding determinants into pharmacophoric descriptors for use in virtual screening HTD validation and/or optimization programs.
An important example of this approach in hit validation stems from a recent paper that identified a small molecule modulator of p53, RITA (reactivation of p53 and induction of tumor cell apoptosis) using experimental HTS [67] . However, unlike previously identified HDM 2 inhibitors, referred to as the nutlins, the authors suggested that RITA targeted p53 inducing is accumulation in tumor cells and thus restoring its apoptosis-inducing function through a mechanism that did not involve targeting the p53-binding pocket of HDM 2 [32] . The authors proposed a unique mechanism of action (MOA) for RITA, whereby it prevented p53 from interacting with HDM 2 [67] by targeting the p53 protein itself. However, Krajewski and colleagues used CSP analysis of both 15 N-labeled p53 and HDM 2 to nicely demonstrate that the p53-HDM 2 complex was not perturbed by the incremental addition of RITA [68, 69] . This example highlights a significant difference between experimental, assay driven HTS in which the readout is gain or loss of function and structure-based high throughput docking that uses a complementary structural approach (NMR) to validate identified "hits". In the absence of confirmatory structural information it is difficult to demonstrate target site specificity and this example clearly supports this limitation.
Structure Activity Relationships (SAR) by NMR
Structure activity relationships (SAR) by NMR is a widely accepted approach in drug discovery programs for generating high-affinity ligands by chemically linking two low affinity ligands targeting multiple subsites, juxtaposed in space and necessary for function [28] . This linked fragment approach is directed using NMR chemical shift perturbation data collected with a 15 N/ 1 H and/or 13 experiments. The success of this approach is dependent upon the identification of two small molecule "hits"/fragments that target nearby sites and are able to be chemically linked/synthesized in a manner that preserves the requisite orientation of each "hit" in 3D space [28] . The increased affinity is the additive effect of joining the two "hits" and it is assumed that the mechanism of hit linkage contributes minimally to the resultant compound other than limiting conformational freedom [70] . Specifically, Oltersdorf et al. [71] have used NMR spectroscopy in combination with parallel synthesis and structure-based design to discover a small molecule inhibitor, ABT-737 of the anti-apoptotic Bcl-2 family of proteins, Bcl-2, Bcl-X L and Bcl-w. Hit compounds were identified within a fragment library and subsequently chemically linked using SAR by NMR directed synthesis. Although ABT-737 bound Bcl-X L with high affinity the presence of 1% human serum albumin (HSA) decreased the affinity ~300 fold, suggesting the presence of a deleterious interaction with HSA [72] . To reduce HSA binding structure-based "lead-optimization" was performed identifying the critical descriptors mediating the interaction between ABT-737 and HSA. Following chemical modification of the cross-reactive groups involved in this interaction, HSA binding was significantly reduced without altering the affinity for Bcl-X L [71] . In addition, this SAR approach has been successful in "fraganomics", in which two simple, weak binding "hits" are chemically linked to create a high-affinity "lead" with a significantly improved K d , that is amenable to further optimization ( [26] and references therein). The significantly higher hit rate for fragment-based screening, which assumes the library being screened is diverse and comprised of "drug-like" fragments that are tractable to further chemical tailoring provides a viable alternative to conventional HTS.
SAR by ILOEs
Pellecchia and colleagues, have recently developed a derivation of SAR by NMR; SAR by interligand nuclear overhauser effect (ILOEs). SAR by ILOE is a powerful reverse chemical genetics approach for identifying target protein "hot spots" and is generally applicable in hitthrough-lead discovery [73] . In this scenario the small molecule "hits" are identified first and the resultant phenotypic response of this interaction is latter determined [73] . This approach takes advantage of the different mechanisms of spin relaxation for bound and free ligands, since the unbound ligand tumbles rapidly in solution providing weak positive NOEs that are opposite in sign to the diagonal peaks in NOESY spectra [74, 75] . However, when the ligand is bound to its protein target the ligand assumes the target proteins relaxation properties, resulting in strong negative NOEs (same sign as the diagonal cross peaks), which are optimal for compounds that are in rapid exchange (K off »1/T 1 , the longitudinal relaxation rate) [73] . If two small molecule hits bind adjacent sites (at a distance <5 Å) on the target protein, strong, negative NOEs (ILOEs) resulting from the interligand nuclear Overhauser effects are observed between the interacting ligand resonances [52, 73, 76] . ILOE buildup curves provide structural guides for chemically linking the two ligands, further ensuring that the inter-nuclear distance and 3D orientation of the interacting ligands are preserved. Since ligand-ligand magnetization transfer is more efficient for larger proteins, ILOE detection is optimized for large protein targets, a trait that strengthens the utility of this approach in evaluating larger, less tractable target space [20] . Using fragment-based screening, molecular modeling and synthetic chemistry, Pellecchia and colleagues have used SAR by ILOE interaction data to rationally design BI-6C9, a small molecule that binds the surface of Bid (member of the Bcl-2 family) preventing its association with the mitochondrial membrane [33] . A logical extension of this approach would be to further validate this newly synthesized "lead" by doping a virtual small molecule library and using HTD to demonstrate that this compound targets the interaction interface, while simultaneously identifying other "hits" that dock as well or better.
LEAD OPTIMIZATION AND VALIDATION Rapid Analysis and Multiplexing Discriminated Uniquely Labeled Proteins Using NMR (RAMPED-UP NMR)
The identification of lead compounds from large chemical repositories is the rate-limiting step in efforts to identify new chemical entities worthy of preclinical/clinical development. RAMPED-UP NMR attempts to expedite and simplify the NMR readout by taking advantage of site specific isotope labeled ( 15 N or 13 C) amino acids, which permits the multiplexing of protein targets whereby a target "decoy" is present in the same NMR sample. The decoy is differentially labeled, using either of the distinct heteronuclei or the same hetero-nucleus label as is in the target but selectively labeling a different amino acid [63] . In addition, to increasing the throughput potential of NMR spectroscopy this approach provides "in-tube" selectivity and specificity measurements for the target being studied and is valid assuming that there are no protein-protein interactions between the target and decoy. The inherent limitations of the method are that the multiplexed proteins must be in similar buffer systems and ideally this is more suited to targets with known structures to permit labeling of amino acids within the active site.
A La Assay to Detect Reactive Molecules (ALARM NMR)
Post HTS filtering has identified additional artifacts that contribute to late stage lead triage including hit-induced target aggregation and/or target-hit reactivity [77, 78] . While small molecules with known reactive groups including epoxides, anhydrides and Michael acceptors are quickly removed from chemical libraries by medicinal chemists, there remains a significant problem with HTS, namely reactive "false positives". Chemical reactivity attributed to active thiol moieties is estimated to cause a 12%-36% false positive rate, which prompted the development of fluorescence-based and NMR-based assays capable of reproducibly evaluating thiol reactivity of targets being evaluated [78, 79] . The A La Assay that has been used to detect Reactive Molecules (ALARM) by NMR measures dithiothreitol (DTT)-dependent 13 C chemical shift changes of the La antigen in the presence of small molecule "hits" [78] . Huth and colleagues at Abbott Laboratories evaluated the sensitivity of their approach using a panel of commercially available drugs [78] . While performing the ALARM screen with the La antigen, a protein that contains two free cysteine residues (which is functionally responsible for stabilizing RNA transcripts), they obtained an unusually high hit rate using 13 C-HSQC CSP analyses of the La antigen methyl groups [78] . Interestingly, when they repeated the ALARM screen with a larger, 46,000 compound repository that included those previous "hits", but now in the presence of DTT not a single "hit" was identified. Huth and colleagues concluded that their high hit rate in the absence of DTT is a spurious result attributed to a highly reactive cysteine thiol that was highly susceptible to "hit" modification [80] , which in turn allowed them to conclude that this target was not tractable to small molecule intervention [78] . Data provided by ALARM screens have been critical for validating or refuting HTS hits prior to excessive lead optimization [78] . This hit validation protocol is rapid, the data are easily interpreted and the approach is sensitive. This NMR-based validation tool is a critical in "hit-through lead" discovery processes, assuming covalent modification of the target protein is undesired.
Pose Scoring
Protein-ligand complex assembly results in CSPs within the binding site of the target and the atoms of the ligand that are responsible for mediating binding at the interaction interface. These data are routinely obtained for the target using 15 N-1 H or 13 C-1 H HSQC spectra (as previously detailed), providing critical descriptor details and, facilitating a better understanding of structure activity relationships. However, these data are limited in that they do not accurately identify the orientation of the ligand within the target-binding site. To circumvent these empirical constraints and accelerate ligand binding validation several groups have described methods to theoretically calculate ligand-induced CSPs [81] [82] [83] [84] [85] . These rapid approaches predict experimentally derived NMR chemical shifts using the modified neglect of diatomic overlap (MNDO) Hamiltonian and gauge atomic orbitals (GIAO). To overcome the inherent size limitations of this approach, the authors identified that when estimating CSPs of larger protein-ligand complexes the density matrix divide and conquer technique, which is capable of handling thousands of atoms, should be used [86] . This approach was validated for the FK506 binding protein in complex with GPI-1046, a peptidyl-prolyl cistrans isomerase inhibitor [81] . Here the theoretically calculated CSPs were found to be in excellent agreement with those experimentally derived from [ 13 C, 1 H] HSQC data [81] . More importantly, this approach was able to differentiate between native (true binding) and decoy (nonbinding, false positive) ligand poses, a critical impediment that all HTS approaches used for small molecule identification and validation must overcome. It is likely that this approach will have a profound impact on the adoption of NMR-based, computational filters enabling in silico HTD "hits" to be streamlined using powerful computing clusters. The potential to theoretically calculate ligand-induced chemical shift perturbations provides a rapid method for validating the accuracy of scoring algorithm used, which remains the Achilles heel of virtual screening approaches ( [87] and references therein). These scoring algorithms must be capable of reproducibly ranking not only the best compound, but also identifying the physiologically relevant pose within the target pocket.
Saturation Transfer Differences
This versatile approach has been used widely to evaluate therapeutic target interfaces of any size, composition or oligomeric state ( [54] and references therein). Saturation transfer difference (STD) NMR uses a selective radio frequency (rf) pulse to saturate target resonances specifically, through the excitation of a narrow spectral window containing only target resonances. The magnetization of these resonances is then propagated efficiently due to the size of the target protein via intramolecular 1 H-1 H cross relaxation pathways within the target and ultimately transferred through intermolecular relaxation mechanisms across the target-ligand interface to the ligand resonances [88] . To ensure that the resonances perturbed are specific for the target-ligand interface, a reference experiment is collected using an identical rf pulse applied off resonance (different spectral window) and then subtracted. This removes spectral artifacts permitting those resonances that experienced saturation and are unique to the target-ligand interface to be identified. If necessary, resonances associated with the target can be removed by R 2 relaxation filtering, which provides a simple 1D 1 H spectrum identifying perturbations of only those ligand resonances involved in binding [80, 89] . STD NMR provides detailed information for the target-ligand interface identifying those interactions that facilitate ligand binding. In the early stages of structure-based drug discovery, detailed structural information is critical for accelerated lead optimization, as has recently been demonstrated for the STD approach, SOS-NMR (Structure information using Overhauser effects and Selective labeling) [80] . Typically for SOS-NMR the target is deuterated at all positions except those amino acids that are being assessed for their contribution to ligand binding [80] . Recently, another STD experiment, ATP-STD NMR was validated for use in identifying novel ATP-competitive kinase inhibitors, a target class that has suffered from high HTS "false positive" rates and a lack of kinase inhibitor scaffolds (poor chemical space representation) in both proprietary and publicly accessible chemical repositories [89] . If the 3D structure of the target is known these data provide an accelerated approach for defining the target-ligand complex structure, providing critical interfacial details without growing crystals or sequentially assigning NMR data. There are several other "diffusion filter" approaches that have been implemented into ligand-screening efforts due to their ease and high sensitivity, for these details see ( [29, 54] and references therein).
It is important to note that the ability of NMR spectroscopy to detect protein-ligand interactions over a range of affinities including weakly binding fragments employed in fragment-based discovery initiatives is powerful. While NMR experiments observing the ligand or protein are capable of providing structural evidence of this interaction, these approaches are potentially limited by the solubility of the protein and/or ligand being studied, which is a common artifact identified by the Shoichet laboratory [90] . However, advances in pulse sequences, and NMR instrumentation, specifically Cryoprobe technology have increased the sensitivity of these experiments and alleviated some of this concerns (as reviewed extensively in [91, 92] ). There are numerous examples demonstrating the power and utility of this approach, further establishing that NMR spectroscopy is an "important driver" in the discovery engine.
FRAGANOMICS
Experimental and virtual HTS approaches that screen libraries comprised of "rule of 5-compliant" compounds have been modestly successful at providing drug-like candidates although recent success suggest that the intensive research efforts in this area are paying off [3, 7] . This problem is further exacerbated by the corporate "screen for drug" philosophy and inherent compound complexity that has been identified in the GSK library and is likely a pervasive property of most proprietary libraries [27, 93] . Additionally, significant late stage attrition rates of new chemical entities that are in preclinical development due to poor chemical integrity, adsorption, distribution, metabolism or excretion (ADME) issues has bolstered the importance of maximizing these drug-like properties early in the hit-through-lead identification phase [12, 94] . While the Lipinski 'rule of 5' [24, 25] remains the industry standard for evaluating lead/drug-likeness and thus oral bioavailability, Congreve and colleagues recently proposed the 'rule of 3' [95] . This 'rule of 3', like the Lipinski drug-likeness descriptors is central to fragment-based lead discovery, limiting that molecular mass (M r ) to 300 Da and lipophilicity (cLogP) to 3 and the number of hydrogen bond donors and acceptors to ≤ 3, in an attempt to maximize the pharmacokinetic (PK) and/or pharmacodynamic (PD) properties of these small molecules. Their rationale is that during lead-optimization, which typically increases the fragment size by several heavy atoms (4) (5) , the cLogP by a single unit, the number of potential hydrogen bonds and aromatic rings that the optimized lead would retain ideal/ industry evaluated PK and PD metrics ( [26, 96] and references therein).
Fraganomics makes use of weak binding, simple molecules of ~120-250 Da that bind the target at high concentrations (1mM), providing a scaffold upon which a high affinity lead could be chemically engineered, while maintaining compliancy with the 'rule of 5' [26, 97] . Structural data from NMR spectroscopy or X-ray crystallography is essential to guide fragment screening and subsequent chemical engineering of the optimized lead, with NMR being particularly suited to this approach given the range of binding typically observed for these small fragments [26] . NMR spectroscopy and particularly structure activity relationships (SAR) by NMR have been implemented into all fragment based approaches including; fragment evolution, fragment linking, fragment selfassembly and fragment optimization ( [26] and references therein). Importantly, NMR permits the entire target to be observed during the construction of the "lead" ensuring binding site specificity. The importance of this approach, which may help rationalize its increased adoption within the pharmaceutical industry, is the need for novel "hits" that are compositionally simple and thus less likely to suffer from poor PD/PK properties during the rigorous lead optimization stage [27, 98, 99] . From a fiscal standpoint the integration of such an approach early in the discovery process would likely reduce corporate R&D costs. However, it is possible that its greatest utility will be the exploration of novel 3D target space that is believed to be intractable, such as proteinprotein and/or protein-DNA interfaces [19, 20, 30] . Although many groups are adopting this approach its use alone and/or partnered with NMR spectroscopy is in its infancy and only time will permit its true utility in drug discovery initiatives to become apparent. An excellent, recent review highlights this discovery paradigm by presenting 25 of these protein targets that were exploited using fragment discovery to identify leads for optimization [26] .
STRUCTURE-BASED HIGH THROUGHPUT DOCKING (HTD)
With the success of several structural genomic initiatives and the increased 3D target space available for structurebased drug discovery initiatives greater emphasis has been placed on computational methodologies, which have become a mainstay in "hit through lead" discovery programs ( [87, 100, 101] and references therein) (Fig. (2) ). Structurebased virtual screening relies on two functions; docking and scoring, which as we will discuss in detail have unique limitations. Scoring reproducibility continues to be the barrier preventing the adoption of this approach industry wide [87, 102, 103] . Docking involves a systematic search of all degrees of conformational freedom, independent of the approach or software employed. The search algorithms used explore the potential energy landscape, which is also referred to as 3D conformational space. This is done in an incremental fashion as to increase the level of complexity minimally, yet with sufficient detail to identify the global energy minimum accurately [104] [105] [106] [107] . Importantly, there are four major classes of scoring functions that complement these docking algorithms, which are responsible for generating accurate ligand poses. The challenge of these scoring functions is in their ability to predict the correct pose and reproducibly rank/score it most favourably, while simultaneously attempting to optimize the requisite pharmacokinetic properties needed for "hit through lead" optimization [103] . Scoring function reproducibility is further complicated by the simultaneous assessment of both the steric complementarity between the ligand and target and the maintenance of chemical complementarity at the interaction interface. Several excellent reviews have recently been published documenting an industry wide attempt to refine both: 1) docking [19, 20, 38, 87, 101, 103] and 2) scoring [108] [109] [110] [111] [112] [113] approaches. These efforts are specifically tailored toward refining and accelerating structure-based drug discovery programs, with special emphasis on the need to exploit novel target space. In this review we will simply provide a synopsis of the various approaches one could use to streamline corporate and/or academic drug discovery initiatives.
LIGAND DOCKING METHODS
Structure-based drug design involving computational docking is dependent on the algorithm's accurate prediction of the correct pose of the active/hit and subsequent rank or score for the correctness or tightness of fit, while simultaneously optimizing for accuracy and speed [109, 114] Fig. (2) . One caveat of this in silico approach is that the pose that is predicted to be the best and thus representative of the active conformation (as defined by crystallographic binding modes), is not always scored/ranked the best, which introduces the potential of false positives, further increasing the complexity of this approach. Proteins are complex molecules comprised of many atoms that are involved in structure and/or function. This complexity increases exponentially when one attempts to computationally map protein-protein and/or protein-ligand interactions in a pairwise atomic fashion. Early docking approaches evaluated only translation and orientation degrees of freedom for the ligand without considering ligand flexibility [115] [116] [117] . A subset of these proteins are believed to be tractable to small molecule intervention, however in order for in silico HTD to be integrated into platforms for discovery that were computationally feasible, several assumptions relating to the complexity of the targets and more importantly the targeted surface were necessary [38] . These limitations that currently permit ligand conformational flexibility but treat the target as a rigid body (with the exception of GOLD, GLIDE, AutoDock and FlexE that permit localized target flexibility around the active site) present several challenges that are currently being addressed. However preliminary studies suggest that the nature of the target and/or its active site may be helpful in guiding the selection of the docking program used in individual virtual screening initiatives [109] . Although the number of algorithms used to dock flexible ligands continues to increase we will only discuss those approaches that have been used and validated extensively [38] . Classically, these algorithms are divided into three families: random or stochastic search, systematic search, and multi-conformer search ( [87] and references therein).
RANDOM/STOCHASTIC SEARCH
These algorithms introduce random changes into a ligand or family of ligands through changes in the conformational, translational and/or rotational properties, using the Metropolis probability criteria to score and evaluate the new ligand configurations [118] . In general these random approaches use Simulated Annealing (SA), Monte Carlo Algorithms and/or Genetic Algorithms (GA's) including the Evolutionary Algorithm (EA's). These GA's are based on the premise of biological competition and population dynamics, using critical parameters that are stochastically varied on chromosomes to provide an ensemble of potential ligand conformations [119] . A Tabu Search (TS) or Hybrid Global-Local search such as the Lamarckian GA (LGA's) evaluates each ligand conformation by iteratively calculating the RMSD between the new ligand conformation and the conformational space previously explored by all other ligands to identify tabu [a change is considered tabu if it is not sufficiently different (RMS <0.75Å) from the previously explored conformation] versus non-tabu changes [120] . [121] . Its search methods include the use of an evolutionary programming genetic algorithm (EGA), which can be partnered with a Hybrid Global-Local LGA that that permits switching between "genotypic" and "phenotypic" space [121] . These algorithms function together using Monte Carlo SA to improve conformational space exploration and ligand convergence, which is critical for ligands possessing greater than eight rotatable bonds. Chromosome mutation and crossover can occur in genotypic space, however the accessible phenotypic space is determined by the energy function [121] . Implementing a local search (LS) engine, such as the "hybrid search LGA" that permits chromosomal crossover, mutation and migration providing offspring with inherited 'environmental adaptations', enhance the GA. The Olson group has recently demonstrated that this adaptive LGA method manages higher dimensionality more efficiently than SA approaches, while demonstrating greater consistency than GA alone [104, 122] .
Automated Docking of Flexible Ligands to
Genetic Optimization for Ligand Docking (GOLD): ( A l g o r i t h m :
G A ) A v a i l a b l e a t : http://www.ccdc.cam.ac.uk/products/ life_sciences/gold/ GOLD, which is available through the Cambridge Crystallographic Data Center (CCDC) utilizes a genetic algorithm that was originally described by Jones and colleagues and an evolutionary strategy involving three genetic operators; crossover, mutation and migration [119, 123] . This GA explores the conformational flexibility of putative poses for a single ligand, while sampling the respective binding modes of each pose into a target that is locally flexible within the active site. GOLD uses a distributive island model for handling the output structures or chromosomes (each chromosome encodes a ligand pose within the target active site) that are assigned a fitness score. This approach allows multiple subpopulations of the ligand to be manipulated rather than a single large population, resulting in improved efficiency of the GA [119] . These genetic chromosomes contain four genes, which encode conformational information for the target and ligand (encoded by two binary strings), and additional genes that have been encoded to efficiently identify hydrogen bonding networks and lipophilic interactions. At each step, mutagenesis within a chromosome can occur or two parental chromosomes can mate to generate children or child chromosomes that are evaluated for fitness to determine their fate. Selection of the highest scoring ligand (chromosome) is based on a linear normalized fitness score comprised of several variables that included: the conformation of the ligand within the active site, least squared placement of the ligand within active site, hydrogen-bonding energy term, steric energy term and internal energy of the ligand, which are summed to provide a fitness score for each ligand [119] . Migration of an individual from one island (subpopulation) to another one can occur, which increases the efficiency of the GA. GOLD, which was the first algorithm to be evaluated on a large dataset of complexes, possesses an empirical free energy scoring function that estimates the free energy of binding permitting inhibition constants, K i to be calculated. Although initial applications of GOLD and the GA employed provided poor convergence results for hydrophobic ligands, GOLD has recently been validated using a test set of 305 diverse protein-ligand complexes and 72% of the top-ranked solutions were deemed accurate using the authors' self-imposed stringent success criteria [124] . The MOE search algorithm uses the Tabu Search (TS) methodology or SA, to sample conformational space that is user-defined within a 3D bounded docking box and is empirically scored to estimate the binding energy [120] . The TS functions by imposing restrictions on previously sampled space, storing this conformational information and thus preventing the continuing 3D search from revisiting that space. MOE-Dock performs a defined number o f independent docking calculations (moves), writing the resultant conformation and corresponding binding energy to a molecular data base file. As previously noted a move is considered tabu if it generates a solution that is not sufficiently different (RMS < 0.75 Å) from those stored, while the highest ranked move is always accepted if its energy is the lowest. The resulting docked complexes are generally subjected to a MMFF94 energy minimization protocol ensuring that the root mean square (RMS) of the conjugate gradient is <0.1 kcal mol -1 . Corrections for electrostatic interactions that result from solvent effects can be implemented at the discretion of the user. Briefly, a generalized Born/surface contact area function that models the electrostatic contribution of solvation to the global free energy in a continuum solvent model is implemented [125] . In a recent paper by Baudry et al. MOE-Dock was used to dock two known substrates (xanthotoxin and bergapten) and two inhibitors (coumarin and pilocarpine) into cytochrome P450 [126] . The family of furanocoumarins represent plant toxins found in insects such as Papilio polyxenes that are used topically in the treatment of a variety of skin diseases and are metabolized by cytochrome P450 monooxygenases (P450s). Their combination of theoretical and experimental docking provided significant structural details pertaining to the position of these toxins within the P450 catalytic pocket, facilitating a better mechanistic understanding of substrate reactivity.
Molecular Operating Environment (MOE)-
PRO_LEADS (Algorithm: TS)
Available at: http://www.protherics.com/crunch/ section5.html PRO_LEADS is a docking algorithm that uses a stochastic evolution of the system directed by a TS that is ranked and scored with an empirical scoring function, ChemScore [127] . Prior to commencing the TS the conformational position and orientation of the ligand are randomized (referred to as the current solution), within the bounding box [120] and an initial energy is calculated. Random moves are then applied to the ligand, generating a population of solutions (typically 100 solutions) that are scored and ranked in ascending order with the best move at the top of the list. The move that is at the top of the list is the best-ranked solution and is defined as the new or current solution with the assumption that it is the lowest energy conformation. Using this current solution another random population of moves is performed, however a tabu list of the previous conformations that were suboptimal directs and/or limits the conformational space sampled to ensure novel 3D space is surveyed by each of the subsequent docking calculations. This process is repeated for a user-defined number of iterations. During this iterative method a list of the 25 most optimal ligand conformations or moves is stored as the 25 current solutions. Should the lowest energy solution from the newly ranked population be of lower energy, it is always accepted as a new current solution, however, if it is not the lowest energy, the best non-tabu solution is then used. A move is considered 'tabu' if it is within an RMSD of 0.75 Å of a previously calculated solution and is stored within the tabu list, which is updated on a first-in first-out basis. PRO_LEADS was validated using three enzymes (thrombin, thermolysin and influenza virus neuraminidase) that were chosen on the basis of extensive ligand-enzyme crystallographic information. In 76% of the cases, PRO_LEADS successfully identified the correct ligand conformation as the lowest energy configuration [128] .
Grid-Based Ligand Docking With Energetics (GLIDE) (Algorithm: MC)
Available at: http://www.schrodinger.com/Products/ glide.html GLIDE, which can be obtained from Schrödinger approximates a systematic search of the positions, orientations, and conformations of the ligand in the receptorbinding site using a series of hierarchical filters, though approximations have been made to improve the computational speed of the approach [105, 129] . The target is defined by 3D shape and other known properties represented on a grid by several different sets of fields that are computed once (efficient), prior to docking, which provides an increasingly efficient method for generating accurate ligand pose. An initial set of ligand conformations is generated through exhaustive search of all torsion-angle minima, and the conformers are clustered in a combinatorial fashion. Each cluster of the ligand, which is defined by a common conformation of the core, but an exhaustive set of side-chain conformations, is docked as a single object within this initial stage. The search begins with a rough positioning and scoring phase that significantly narrows the 3D search space. This process reduces the number of poses under consideration to a few hundred prior to performing rigorous energetic and gradient evaluations, and simultaneously prevents a random approach that suffers from poor sampling of the entire search space [105] . These selected poses are minimized using a pre-computed OPLS-AA van der Waals force field [130] and electrostatic grids that define the target. Finally, using a Monte Carlo procedure the 5-10 lowestenergy ligand poses are evaluated for the presence of nearby torsion minima, while permitting the peripheral groups to be correctly oriented. Although typical molecular mechanics scoring functions provide a reasonable model for predicting a ligand's binding mode, they are not capable of ranking different and/or charged ligands. GLIDE uses the GlideScore scoring function for predicting binding affinity, which expands upon the ChemScore scoring function to include force field-based components and additional metrics for evaluating solvation and repulsive interactions that penalize target-ligand interactions that violate these physiochemical properties [129] . The choice of the best pose is made using the energy score model (Emodel) that combines the energy grid score, GlideScore, and the internal strain of the ligand. Halgren and colleagues recently evaluated GLIDE in a database screen with diverse protein receptors identifying that the most recent version of GLIDE; GLIDE 2.5 is qualitatively advanced in scoring accuracy and virtual screening efficiently when compared with its predecessor, but suffers if the target site is hydrophobic [129] . Schrödinger is currently working on a version of the program that will likely address this deficit, while simultaneously improving the molecular modelling mechanics defining the active site geometry using continuum salvation models.
In a recent study carried out at Johnson and Johnson, Kontoyianni and colleagues compared the accuracy of 5 docking algorithms that are extensively used including: DOCK, FlexX, GLIDE, GOLD and LigandFit [109] . In terms of docking accuracy, GLIDE and GOLD outperformed the other programs in their ability to reproduce experimentally observed binding modes, however the authors cautioned that when using a representative study the conclusions are only applicable to the complexes studied and should not be extrapolated to all 3D space [109, 131] . GLIDE provided the greatest number of accurate poses for the complexes evaluated with 85% of the binding modes determined having an RMS deviation of 1.4Å or less when compared with the co-crystallized structure. However, it is important that in addition to predicting the correct binding pose that the scoring algorithm used is capable of subsequently ranking these poses in a manner that provides an enrichment of the true hits, while removing geometric and/or hit list decoys [35] . In order for computational docking programs to be of practical use in virtual screening, they must enrich the fraction of suitable lead candidates in a chemical database, requiring less of the database to be searched, which ultimately streamlines this process while reducing R&D costs. Once again GLIDE outperformed the competition with the target test set used, and outperformed the next-best algorithm, GOLD two-fold. Another common problem in structure-based HTD is the complexity of the target active site and/or ligand [87] . Once again GLIDE performed well with target active sites that were hydrophilic or lipophilic, and was less prone to errors caused by the complexity of the ligand, as demonstrated by its ability to dock molecules comprised of 15 or more rotatable bonds. As noted, one true limitation or caveat of this approach remains the ability to score and/or rank the physiologically relevant pose correctly [87, 111, 132] . In this test set GLIDE ranked 26 of its 39 accurate poses (67%) among the top six poses following scoring with GlideScore, suggesting that GLIDE also has a powerful scoring function [129] .
SYSTEMATIC SEARCH/INCREMENTAL CONST-RUCTION
An alternative to the previously discussed stochastic methods involves the use of algorithms that attempt to perform a systematic conformational search of all possible conformers and degrees of freedom to enhance the likelihood of identifying the correct conformation, which can be computationally expensive [87] . An alternative to these programs that avoids this exhaustive and potentially limiting approach involves the use of incremental construction algorithms, which place a rigid core (base) fragment into the target active site and then incrementally grow the ligand by adding flexible ligand constituents of the ligand was originally proposed by Leach and Kuntz [133] . This incremental construction approach involves three operations: defining the core fragment, core fragment placement and then incremental ligand construction [134] .
DOCK
Available at: http://dock.compbio.ucsf.edu DOCK a program that was developed in the Kuntz group was the first incremental construction algorithm for docking [117, 135] . In this initial evaluation of the incremental construction algorithm, different rigid fragments of the ligand were docked into the target independent of one another. In the second stage, each of the rigid fragments was linked in a manner analogous to the parental compound, if and only if they were within bonding distance. Subsequent implementations of the algorithm involved a more rigorous, 3D, conformational search of the potential degrees of freedom for the flexible constituents of the ligand. All possible dihedral angles were conformationally sampled, however the number of dihedral angles explored following addition of these constituents was constrained to prevent a combinatorial explosion. A pruning algorithm is included to remove significant steric clashes and/or other unfavourable conformations during this construction process, thus limiting the complexity of this potential problem [136] . DOCK places the core fragment within the active site using steric complementarity. Following core fragment placement the flexible side chains are grown from the core one bond at a time by systematically exploring each bond's pose space [87] . A GA was also implemented in the program DOCK, which docks the complete ligand into the active site or a rigid fragment of the ligand in the first stage. A sphere-based GA was included in DOCK 4.0 enabling either of these two choices to be performed. This GA ensures broad sampling within the target active site for a rigid ligand, while the explicit-orientation-based method, which provides significantly more accurate ligand poses offers detailed conformational sampling for the ligand within a defined region of the target active site for a flexible ligand [137] . DOCK3.5 [138] was recently used in a screen of protein tyrosine phosphatase 1B (PTP-1B) in which 235,000 commercially available compounds (ACD, BioSpecs and Maybridge databases) were docked into the X-ray crystal structure of PTB-1B (PDB entry 1pty) using a site defined by two bound phosphotyrosine molecules [139] . Following docking the top-scoring 1000 molecules (500 for the ACD and 500 for the combined BioSpecs and Maybridge databases) were considered for further evaluation and a total of 889 molecules were actually available for further evaluation. Following user intervention (visual inspection of calculated poses) 365 compounds were chosen for testing and of these, 127 molecules were found to be active with an IC 50 <100 µM, providing a hit rate of 34.8%. [140] [141] [142] . Similar to DOCK, FlexX docks ligands incrementally as has been described previously and will only be briefly commented upon here [134] . The algorithm used by FlexX is based on the model of molecular interactions defined by Bohm [143] and Klebe [144] and is divided into three segments: core or base selection, core placement, and incremental complex construction [134] . The ligand to be docked is initially fragmented resulting in the generation of several base fragments, the selection of which is highly dependent upon the number and specificity of contacts made between the respective fragments and the target active site, which would provide the algorithm with a single, preferred binding orientation. Two unique algorithms focused on resolving geometric ambiguity are responsible for placing the base fragment. The first uses triples of interactions between the base and target, and if the number of placements for the base is low, an alternative algorithm that pairs interaction centres is used [134] . Following base placement, the remaining constituents of the ligand are divided into small fragments and incrementally "grown" onto the base alternatives. This incremental construction method provides a tree search, with unproductive (energetically unfavourable) branches being pruned as quickly as possible within this iterative stage. Following the addition of incremental pieces of the ligand, the ligand is then ranked and the best ranked solutions are kept at each level of the tree ensuring that the energy of the ligand is minimized, while pose clustering removes similar configurations. FlexX differs from DOCK in that the placement of the rigid core fragment is based upon interaction geometries between the ligand fragments and target active site descriptors. These interacting groups and/or descriptors that define critical features of the active site are primarily hydrogen-bond donors and acceptors, as well as hydrophobic groups. FlexX-Scan is recent docking program that was developed to increase the speed of virtual screening, using the FlexX incremental construction algorithm [145] . Based on the notion of molecular "hotspots", the authors have demonstrated a comparable enrichment for the 200 protein ligand test set to that obtained using FlexX, however the average computing time per compound was only 5-10s. FlexX was recently used to dock and score ligands into Carbonic Anhydrase II (CAII), resulting in the successful identification of a subnanomolar inhibitor [146] . This docking study involved approximately 90,000 molecules screened from the Maybridge and Leadquest databases, which included 35 known CAII inhibitors. Prior to docking these compounds they identified critical interaction determinants or "hot spots" that were used in creating a pharmacophore model, which was implemented into the screen. Their screen resulted in 3314 new molecules with varying degrees of potency, which were taken to the next stage of discovery. In the second stage these 3314 molecules were rank-ordered using FlexS, which evaluates their potential binding affinities by comparing them with a known, reference compound. In the third and final step the 100 best-ranking molecules were docked into the binding pocket of CAII using FlexX. Of these solutions the best 13 compounds were chosen for in vitro evaluation and three inhibitors demonstrated IC 50 values of <1 nM. Two of the subnanomolar hits were co-crystallized with CAII, and the binding mode/pose identified by FlexX, and subsequently ranked the highest by DrugScore was found to be in good agreement with the experimentally determined structures. This pivotal study yielded two important insights. The first being that water molecules play an important role during the docking process, with four conserved water molecules identified by superposition of all complex-and apostructures of CAII. Inclusion of these solvent molecules in the docking process added to the steric restriction of the binding pocket and led to better solutions. Second, despite the successful identification of high-affinity ligands/binders, they observed a poor correlation between calculated IC 50 values and the binding affinities predicted by FlexX score or DrugScore.
HAMMERHEAD / SURFLEX Available at: http://www.biopharmics.com
Hammerhead [147] and Surflex [106] were developed at Arris Pharmaceutical Corporation and Biopharmics (UCSF Cancer Research Institute and Comprehensive Cancer Centre) respectively. In Hammerhead, the ligand is divided into sections to initially generate head fragments. This is followed by a systematic search that is used to generate a diverse set of fragment conformations. These fragment conformations are then aligned to hydrophobic or hydrogen bonding groups within the target protein and scored using an empirical calculation to determine binding affinity. In each successive stage of alignment a steepest-descent optimization is performed to enhance the score. Those fragments scoring the best (highest) are deemed the head fragments. Again using an incremental construction method, the tails (or remaining fragments) are added individually to these head fragments. At each construction step the best scoring orientation is then retained for the addition of the next fragment. It should be noted that FlexX and Hammerhead use a scoring function to rank intermediate stages of the construction algorithm, further preventing a combinatorial explosion. The algorithm was evaluated using four complexes; and in four complexes the docked structures has an RMSD of 1.7 Å or less when compared with the known complex.
Surflex
Surflex [106] is a new docking method that combines Hammerhead's empirical scoring function with a morphological similarity method to generate ligand fragment poses [106] . Using an active site ligand that has been optimized for interacting within the active site (a protomol) as the comparative standard for generating an ideal molecule or fragment pose, Surflex then fragments each ligand, takes each fragment and conformationally searches all 3D space and then iteratively aligns these fragments with the protomol. The aligned fragments are scored after which they are either kept or discarded using Hammerhead's scoring function [106] . An evaluation of this approach by an independent research group demonstrated that Surflex docking provided reproducible enrichment and docking accuracy, supporting that it is a competitive alternative to other available methods [110] .
MULTI-CONFORMER METHODS
Flexible Ligands Oriented on a Grid (FLOG)
FLOG identifies ligands from a database that are complementary to the active site of the target, for which a high-resolution structure is known. The philosophy of this algorithm is similar to that of DOCK [117] , however this algorithm considers 25 explicit conformations of each ligand, permitting conformational flexibility. A cliquefinding algorithm is used for determining allowed sets of distances between the ligand and target protein, which generates preliminary orientation properties for each candidate ligand within the active site. The resultant ligand is then superimposed onto the target protein interaction site and optimized using a simplex algorithm. The target is represented as a grid and each orientation of the ligand is scored, using a function that includes explicit terms for van der Waals, electrostatics, hydrogen bonding and hydrophobic interactions [148] .
FRED(Fast Rigid Exhaustive Docking)
Available at: http://www.eyesopen.com FRED, which was developed by EyesOpen Scientific Software is a command driven program that takes as input a multi-conformer library/database of one or more ligands, a target protein structure, a box defining the active site of the protein and several optional command-line parameters that are user defined. The ligand conformers and target structure are treated as a rigid body during the docking process. FRED's docking strategy is to exhaustively score all possible positions of each ligand within the active site. The exhaustive search permits rigid rotations and translations of each ligand conformer, a strategy that completely avoids sampling issues associated with stochastic methods used by many other docking programs (GOLD, FlexX, DOCK and GLIDE). The time required to dock each ligand using FRED is a few seconds, which is significantly superior to these same docking programs that measure docking time per ligand in minutes (exception as noted FlexX-Scan). FRED employs Parallel Virtual Machine (PVM) to distribute the computational resources needed over multiple computers/processors, which is another success in the goal of FRED, which was to substantially reduce the time needed for virtual screening. FRED docking roughly consists of 2 steps: shape fitting and optimization. During shape fitting, the ligand is placed into a grid box with 0.5Å resolution encompassing all active-site atoms, including hydrogen atoms using a smooth Gaussian potential. A series of three optimization filters are then used, which (1) refine the position of hydroxyl hydrogen atoms of the ligand, (2) use rigid body optimization, and (3) finally optimize the ligand pose in terms of dihedral angle space, which takes advantage of four potential scoring functions: Gaussian shape scoring, ChemScore, Piecewise Linear Potential (PLP), and ScreenScore [149] .
DIFFERENCES BETWEEN DOCKING AND HIGH-THROUGHPUT DOCKING
These computational docking algorithms have an obviously scalable function making them powerful computational approaches for evaluating more than a single ligand, as is the situation for High Throughput Docking (HTD) screens of proprietary and/or publicly accessible repositories of drug-like compounds (Fig. (2) ). There are several advantages to this in silico HTD approach for the identification and subsequent optimization of "hits", not the least of which are the financial and personnel resources needed for experimental HTS driven therapeutic discovery, which precludes many academic laboratories from pursuing translational studies focused on the discovery of novel therapeutic entities. Unfortunately, this is at odds with the current need for new therapies and the translational mantra of the federal funding agencies in both Europe and the Americas. The extension of these docking programs to HTD required methods that optimize two benchmarks of virtual screening, speed and accuracy, which are dichotomous by nature. In attempting to achieve these goals several docking programs have reduced the docking time per ligand, which has been possible due to significant advances in computational power including faster clock speeds, larger word size, and parallel computer clusters that have been supported by the use of scoring grids and approaches that allow the target surface to be represented as a molecular surface. To date structure-based HTD screening initiatives have achieved significant milestones including enriching active compounds and in several situations identifying new ligands or hits that are subsequently optimised to become true "leads" [45] . However, additional efforts and a considerable synergistic interplay between docking and scoring is necessary if we hope to achieve the ultimate goal of accurately identifying the physiologically important binding pose and/or energy, versus simply identifying and enriching drug-like "hit" compounds in a reproducible manner. An additional caveat of virtual screening is need to account for, and more accurately predict active site plasticity and/or flexibility, which is computationally expensive and remains poorly understood ( [150] and references therein). As stated earlier the ability to reproducibly score/rank actives in the correct binding mode remains the Achilles' heel of HTD, however several groups have demonstrated the target specific effectiveness of certain scoring functions, which suggests one approach to overcoming this problem [151, 152] . If the remaining obstacles are to be eradicated in the foreseeable future, we will need to improve both the speed with which we explore conformational space, and the extent of 3D space that is sampled. As noted this will and can only happen if we use more sophisticated scoring functions capable of handling queries concerning the energetics of solvation, electrostatics and/or non-polar interactions, which are currently poorly evaluated [45] . Several excellent reviews have been dedicated to identifying the limitations of scoring and so we will only briefly mention this here [108, [153] [154] [155] [156] . With significant progress in many structural genomic initiatives, structure-based virtual screening partnered with downstream structural tools that evaluate and guide optimization is quickly being adopted as an attractive alternative to experimental HTS.
SCORING
While the docking step is an accepted and efficient tool, the post-processing scoring and ranking of hit ligands has impeded attempts to improve the reproducibility and accuracy of the HTD approach. The majority of scoring functions published have been developed in support of, and specifically suited to, a specific docking method. However, scoring functions used to rank HTD "hits" do not have to be, and probably should not be, biased toward a specific docking method but rather function to estimate the binding energy, and binding mode of the ligand within the target active site, independent of the docking program and target being screened. That said regardless of the function applied ligand scores are known to scale poorly with molecular mass and the number of rotatable bonds within a given ligand. Similarly, it is well established that large ligands have the potential to form many interactions within the spatially restricted active site. Their inherent size and complexity contributes to both the number and specificity of these interactions, providing better scores than the scores derived for smaller ligands and/or fragments. Nonetheless, an additional caveat of many scoring functions is the entropic penalty of rotatable bond immobilization, which is not a component of many scoring functions used and scales as the number of such bonds increases. If these entropic penalties are included, flexible molecules tend to score lower than more rigid ones. Just as the virtual 3D space for ligands is boundless, targets and more specifically their active sites are uniquely complicated, comprised of structural and physiochemical properties including: shape, size, depth, hydrophobicity, lipophilicity and electrostatic potential all which should be evaluated in hierarchical fashion by the scoring function implemented. There are essentially three classes of scoring function: force field-based, empirical and knowledge-based [87] . While each scoring function has been validated using "test sets of targets" for the docking program/s that use it, the number of false positives identified in HTD screens remains a significant bottleneck and barrier to further adoption of this important drug discovery tool.
Toward a better understanding of scoring functions and their impact on; enrichment [132] , the combination of docking and scoring [157] , criteria for consensus scoring [155, 156] , a multiple scoring function [109] [110] [111] 158] and machine learning [154, 159] a wealth of literature has been published. While all of these approaches permit a more rigorous identification of the correct ligand pose, none of these approaches use a strategy that trains the scoring function to recognize and discard incorrect poses (true negatives) through the use of a ranked-based non-linear consensus scoring scheme in the absence of known inhibitors an approach that we are currently optimizing in our laboratory (Betzi et al., in revision). This method of parsing large databases through virtual screening approaches will help reduce the number of false positives, providing a significant enrichment of true "hits" for further evaluation in experimental HTS experiments and/or subsequent evaluation in vitro. One advantage of this approach is that our consensus scoring function is a non-linear, ranked-based scoring function and not a value-based function. Briefly, we have used a Neural Network Analysis for learning set evaluation of the scoring results we have extracted from the five scoring functions within Cscore (FlexX Score, G_Score, D_Score, ChemScore, and PMF Score) following a FlexXbased (TRIPOS) HTD screen. We have comparatively evaluated the ability of our generalist/consensus score, GFScore (available at http://gfscore.cnrs-mrs.fr) with each of the other scoring functions including Cscore (TRIPOS) (Betzi et al., in revision). GFScore eliminated 80% of the database with a confidence level of 95% while the next best function (FlexX Score or G_Score) provided a confidence level of only 65%, having eliminated the same percentage of the database. Together these data provide important insight into some basic rules that appear to govern the fitness of each scoring function, supporting the notion that scoring function accuracy may indeed be influenced by the chemical space being targeted.
VALIDATING TARGET-LIGAND INTERACTIONS: A COMBINATION OF IN SILICO SCREENING AND NMR SPECTROSCOPY
In light of the discussed deficiencies of post-processing filters of HTD, an alternative approach that is able to more precisely identify true positives from these HTD "hit lists" is clearly needed. One promising alternative involves combining HTD screens with a biophysical method such as NMR, which as previously discussed in detail, is an excellent tool for confirming site-specific binding in a dynamic, aqueous environment that can approximate the physiological environment of these target-ligand interactions (Fig. (3) ). A recent NMR-based screen was used to identify target drugability, which is important to define early in the discovery process and could potentially streamline drug discovery initiatives, while also permitting novel chemical space for HTD-NMR approaches to be easily evaluated [21] . Assuming that the structure of the target being screened is known and this target protein is amenable to modern recombinant expression, which facilitates the production of an isotopically enriched [ 15 N, 1 H] or [ 13 C, 1 H] NMR sample, any of the "hit identification/ chemical shift perturbation analysis" approaches previously detailed (SAR by NMR, SAR by ILOEs) could be used as a post-HTD filter for the identification of true binders or positives that have a demonstrable affinity for the target (Fig. (3) ).
As mentioned often one of the critical limitations of HTD is the ability to rapidly, and reproducibly identify and rank true positives, in the context of a high false positive rate. HTD combined with NMR (HTD-NMR) approaches permit only those ligands identified as positives in the HTD screen to be evaluated for binding to the target using NMR (or vice versa) Fig. (3) . NMR could then be used to enrich the hit rate, in that only those ligands that bind to the target as defined by chemical shift perturbations, NOE-based contacts or saturation transfer across the target-ligand interface would be subjected to further "lead-optimization" [160] . In addition, if one collects a 1D 1 H NMR spectrum of the ligand alone and heteronuclear 15 N NOESY-HSQC spectra of the target alone and in complex with a "true positive" ligand, then requisite 3D spatial information at the target-ligand interface can be identified. These data, which are easily identified as new resonances within the complex spectrum provide through space intermolecular NOEs between the ligand and target that further define the orientation and alignment of the ligand within the target active site [71, [160] [161] [162] . These experimental NOEs, which are collected and analyzed with ease and speed, are then incorporated into the HTD screen as pharmacophoric filters, to structurally guide and refine the 3D space to be explored using docking. Since conformational perturbations are observed for both the side chain (of the ligand) and the backbone (of the target) the user can more clearly use these data to propose a mechanism of action/binding. Together these data could be used to help select the scoring function that would be most suitable for the target being screened, which may help preferentially rank and score the correct ligand binding pose with significant accuracy (currently being evaluated). Although adoption of this combinatorial approach is in its infancy several laboratories have been successful in using structural information to guide, "hit" identification and subsequent "lead optimization" for several target classes including matrix metalloproteinases and DNA gyrase [71, 160] . The process of hit-through-lead development is an ideal application of these robust tools, whereby lead optimization is structurally guided in an iterative approach that cycles between virtual screening and rapid NMR data collection. Fig. (3) . Acceleration of the Drug Discovery Process: Combining HTD with NMR. A) This schematic representation of a target protein interacting with small molecules and/or fragments identified using NMR (detailed in Fig. (1) ) or HTD illustrates a current limitation of these approaches, differentiating between "true positives/NMR binding molecule", "false positives/ NMR non-binder or bad binder" and decoys that bind the target but not within the active site. Decoys are potentially very expensive and are often problematic in experimental HTS, resulting in extensive R&D costs. B) NMR is one of the structural tools that provide direct binding evidence and more specifically identifies where the "hit" binds the target protein, allowing decoys to be quickly identified prior to stages of validation and optimization. Simple HSQC experiments will provide CSP data identifying true positives and decoys, while simultaneously allowing false positives to be discarded due to a lack of interaction. Dashed lines illustrate the chemical shift perturbation of some peaks within the HSQC in presence (filled circles) of small molecule hits identified using in silico approaches. If the modified peaks correspond to residues within the active site (performed following NMR assignment of all HSQC peaks), the molecule is classified as "hit". However, if the peak that is conformationally perturbed is within a distinct surface of the target protein (that is not a part of the site being targeted) the small molecule is a hit list and/or geometric decoy. C) If these NMR approaches are downstream of HTD involving the use of a generalist scoring function, then the process of hit validation and optimization is streamlined enabling much of the database to be discarded. The enrichment of the remaining hits accelerates the identification of those compounds to be validated by NMR. As we have recently demonstrated, the use of structurebased, pharmacophoric filters combined with a robust generalist scoring function eliminates 90% of the database. However, the prevalence of false positives necessitates the use of NMR to remove the false positives and decoys previously mentioned, providing a more efficient and cost effective development strategy.
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